First-in-man clinical study of ACOU0085 in patients with age-related hearing loss
With its first clinical study underway, Acousia is taking significant strides towards achieving its goal of developing novel medicines that enhance and preserve natural hearing for patients with SNHL.
Acousia develops small molecule drug candidates as a first-line treatment for patients in need of immediate, high, and localized drug exposure to help preserve their hearing. Following the CTA (Clinical Trial Authorization) from the German BfArM (Federal Institute for Drugs and Medical Devices), Acousia has commenced its first clinical study of ACOU085 in patients with age-related hearing loss. Furthermore, the next generation of drug candidates are already in the early stages of development.
Our therapy approach is a dual mode of action that is suitable for both acute and chronic hearing loss and strives to both enhance and preserve a patient’s natural hearing ability. The different chemical makeups of our small drug molecules, as well as their modes of administration, are specifically designed to target acute, permanent, and progressive sensorineural hearing loss.
Latest news
Pipeline and programs
Acousia is developing a series of small molecule drug candidates for local and systemic treatment of different forms of hearing loss. While the first ACOU085 clinical study in patients with age-related hearing loss started in January 2022, next generation drug candidates are being thoroughly characterized in a range of both specialized and standard preclinical models and assays.
Indication
Cisplatin induced hearing loss
Aminoglycoside ototoxicity
CI surgery hearing preservation
Sudden SNHL
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Acute otoprotection/prevention of hearing loss
Cisplatin induced hearing loss
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Aminoglycoside ototoxicity
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
CI surgery hearing preservation
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Sudden SNHL
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Age-related hearing loss
Chronic hearing loss
Hearing aid synergistic enhancement
Chronic noise overexposure
Chronic hearing enhancement and preservation
Age-related hearing loss
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Chronic hearing loss
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Hearing aid synergistic enhancement
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Chronic noise overexposure
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II
Hearing enhancement/preservation
Early Stage
Hearing enhancement/preservation
Discovery
In-vivo Poc
Preclinical
Phase I
Phase II